Lyell Immunopharma, Inc. expected to post a loss of $2.08 a share - Earnings Preview

Lyell Immunopharma

07/08/2026 23:49

Lyell Immunopharma, Inc. LYEL.OQ LYEL.O is expected to  show a fall in quarterly revenue when it reports  results  for the period ending September 30 2026
The South San Francisco California-based  company is expected to report a 78.1% decrease in revenue to $3.29 thousand from $15 thousand a year ago, according to the mean estimate from 7 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Lyell Immunopharma, Inc. is for a loss of $2.08 per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and 1 "sell" or "strong sell."  
The mean earnings estimate of analysts had risen by about 2.1% in the last three months. ​
Wall Street's median 12-month price target for Lyell Immunopharma, Inc. is $41.50, about 182.1% above its last closing price of $14.71
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Jun. 30 2026
-2.03
-2.02
-1.92
Beat
4.8
Mar. 31 2026
-2.35
-2.36
-1.10
Beat
53.5
Dec. 31 2025
-1.89
-2.23
-7.50
Missed
-236.1​
Sep. 30 2025
-2.66
-2.64
-2.13
Beat
19.4
​​Jun. 30 2025
-3.52
-3.58
-2.89
Beat
19.3
Mar. 31 2025
-3.53
-3.60
-3.54
Beat
1.7​
Dec. 31 2024
-2.63
-3.40
-4.00
Missed
-17.6
Sep. 30 2024
-3.79
-4.00
-3.40
Beat
15
This summary was machine generated August 7 at 22:49 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)